Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Additional Information (Detail)

v2.4.1.9
Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)
 0 Months Ended 12 Months Ended
Aug. 12, 2014
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Mar. 17, 2014
Accounting Policies [Line Items]          
Deferred financing costs   $ 6,000us-gaap_DeferredFinanceCostsNet $ 43,000us-gaap_DeferredFinanceCostsNet    
Percentage of tax benefit likely of being realized   50.00%cndo_PercentageOfTaxBenefitLikelyOfBeingRealized      
Restricted Cash and Cash Equivalents   14,600,000us-gaap_RestrictedCashAndCashEquivalents      
Gain (Loss) on Sale of Assets and Asset Impairment Charges   400,000us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges      
Long-term Investments   4,160,000us-gaap_LongTermInvestments 0us-gaap_LongTermInvestments   250,000us-gaap_LongTermInvestments
Fair Value, Assets Measured on Recurring Basis, Change in Unrealized Gain (Loss) 293,000us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss        
Equity Method Investments, Fair Value Disclosure   4,160,000us-gaap_EquityMethodInvestmentsFairValueDisclosure      
Interest Expense, Debt   1,300,000us-gaap_InterestExpenseDebt 1,900,000us-gaap_InterestExpenseDebt 670,000us-gaap_InterestExpenseDebt  
CB Pharma Acquisitions Corp [Member]          
Accounting Policies [Line Items]          
Fair Value, Assets Measured on Recurring Basis, Change in Unrealized Gain (Loss)   1,200,000us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember 		     
Equity Method Investments, Fair Value Disclosure   3,900,000us-gaap_EquityMethodInvestmentsFairValueDisclosure
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember 		     
CB Pharma Acquisitions Corp [Member] | Third Party [Member]          
Accounting Policies [Line Items]          
Long-term Investments   2,700,000us-gaap_LongTermInvestments
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= cndo_ThirdPartyMember 		     
Employee Stock Option [Member]          
Accounting Policies [Line Items]          
Short-term Investments   300,000us-gaap_ShortTermInvestments
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember 		     
Hercules Note Payble [Member]          
Accounting Policies [Line Items]          
Restricted Cash and Cash Equivalents   600,000us-gaap_RestrictedCashAndCashEquivalents
/ us-gaap_DebtInstrumentAxis
= cndo_HerculesNotePaybleMember 		     
Debt Instrument, Periodic Payment   14,000,000us-gaap_DebtInstrumentPeriodicPayment
/ us-gaap_DebtInstrumentAxis
= cndo_HerculesNotePaybleMember 		     
Long-term Investments   200,000us-gaap_LongTermInvestments
/ us-gaap_DebtInstrumentAxis
= cndo_HerculesNotePaybleMember 		     
Interest Expense, Debt   845,000us-gaap_InterestExpenseDebt
/ us-gaap_DebtInstrumentAxis
= cndo_HerculesNotePaybleMember 		1,700,000us-gaap_InterestExpenseDebt
/ us-gaap_DebtInstrumentAxis
= cndo_HerculesNotePaybleMember 		609,000us-gaap_InterestExpenseDebt
/ us-gaap_DebtInstrumentAxis
= cndo_HerculesNotePaybleMember 		 
Hercules Note Payble [Member] | Third Party [Member]          
Accounting Policies [Line Items]          
Interest Expense, Debt   $ 15,000,000us-gaap_InterestExpenseDebt
/ us-gaap_DebtInstrumentAxis
= cndo_HerculesNotePaybleMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= cndo_ThirdPartyMember